Due to the prevalence of deleterious, germline BRCA mutations in TNBC, the study opened possibilities to target PARP and treat these cancers specifically, leading to the development of Lynparza and Talzenna (Collignon et al. 2016; Farmer et al. 2005). This evidence concerns the gene PARP1 and cancer.